p230 – Effective December 11th, this test will be
updated to be a Qualitative assay.
- Results will be reported out as Detected
or Not Detected.
- The analytical sensitivity of the test
- The result of this test should not be
used as the sole criterion for confirming a diagnosis of CML.
Correlation with cytogenetic, FISH, and hematologic findings is highly
- Monitoring of positive p230 cases can be
achieved using this test in combination with the BCR/ABL1/ASS1
t(9;22) FISH assay.
There’ll be no changes in
CPT codes and pricing. This update applies only to cases accessioned from
Monday, December 11th.
The Early-stage NSCLC Panel analyzes 4 actionable and informative early-stage NSCLC biomarkers, EGFR (PCR), ALK (FISH), ROS1 (FISH), PD-L1 22C3 (IHC), relevant for diagnostic evaluation and therapy-selection. This panel is aligned with emerging published clinical trial evidence and the latest clinical testing guidelines, associated with approved targeted therapies. For more info, please contact your local NeoGenomics representative or visit the Early-stage NSCLC webpage.
New versions of the solid
tumor test requisitions listed below, aligning with recent test updates, are
available for download on our website.
For paper copy orders, please contact our Client Services team.
FOLR1 IHC CDx Sponsored Testing Program Request Form ‒ version 110923
Breast Cancer Test Requisition ‒ version 110923
will be at the San Antonio Breast Cancer Symposium (SABCS)
is thrilled to be exhibiting at this year's San Antonio Breast Cancer Symposium
(SABCS). NeoGenomics leverages its leadership in precision diagnostics to
deliver a complete suite of tests that meet the clinical demands for breast
cancer patients at any stage.
You will find us at Booth #841. Visit our webpage
to schedule a meeting with a NeoGenomics representative to learn more and be
sure to register for our product theater featuring RaDaR® MRD.